Metsera Confirms Feasibility Of Monthly Dosing Of Obesity Drug Candidate
The Phase IIa data for the next-generation GLP-1 agonist showed a decent efficacy profile with weekly dosing, but the company said it also supports giving the drug monthly.
The Phase IIa data for the next-generation GLP-1 agonist showed a decent efficacy profile with weekly dosing, but the company said it also supports giving the drug monthly.